ArticleJNCI cancer spectrum2018

Prospects for Minimal Residual Disease as a Surrogate Endpoint in Pediatric Acute Lymphoblastic Leukemia Clinical Trials.

Lisa M McShane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.